Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, November 2001, p. 2987-2990, Vol. 45, No. 11
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.11.2987-2990.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
GUEST COMMENTARY
Critical Annotations to the Use of Azole
Antifungals for Plant Protection
Herbert
Hof*
Institute for Medical
Microbiology and Hygiene, University of Heidelberg, Mannheim, Germany
 |
INTRODUCTION |
Fungal infections of plants cause a
considerable loss of crop yields worldwide. In addition some fungi,
such as Fusarium spp., while growing on plants are able to
produce mycotoxins which can seriously harm the consumers. Hence, it is
understandable that antimycotics are used in agriculture to control
fungal growth on plants and fruits. Antimycotics are used also to
prevent or to ease the problem of postharvest spoilage of these plants
and fruits.
Various compounds have been described for their antimycotic activity
against a broad range of fungi. Many of these compounds are potentially
useful in plant protection. Among them, azoles are widely applied,
besides dithiocarbamates, strobilurins, and benzimidazoles. Thousands
of tons of azoles are sold annually for the purpose of plant
protection. According to the instructions of manufacturers, about 100 g/ha should be used in the field. In other words, approximately 10 mg
of azoles are finally applied on 1 m2 of plant
surface. Multiple applications per year are sometimes necessary, for
example, during rainy seasons.
 |
SOME REASONS FOR THE MASSIVE USE OF AZOLES IN AGRICULTURE |
There are several obvious advantages of azoles over other
antimycotic agents. Azoles are not only inexpensive but they also have
a broad spectrum of antifungal activity. They are effective against
mildews and rusts of grains, fruits, vegetables, and ornamentals; powdery mildew in cereals, berry fruits, vines, and tomatoes; leaf
spots and flower blights in flowers, shrubs, and trees; and several
other plant pathogenic fungi. Owing to a systemic action against
invaded fungi, azoles, in contrast to other available antimycotics, are
not just applied in preventing plant infection but also for treatment.
One particularly interesting feature of azoles is their long-lasting
stability. Some azoles could remain active in certain ecological
niches, e.g., in soil and water, over months with only slight changes
in their chemical structures, e.g., loss of some side chains. The
half-time of triadimenol, a primary metabolite of triadimefon, ranges
from 110 to 375 days in soil (18). Consequently, azole
residues have been detected in various food items, for example, commercial strawberry samples (26), grapes
(1), or peppermint (5), reaching peak values
of up to 0.5 to 0.8 mg/kg. High levels of azole residues were also
detected in carrots during routine monitoring (6).
Although the pesticide residues found in bulk samples have not reached
health hazardous toxic levels, the amount of such remnant pesticides
could, however, vary significantly in single items. It has been
reported that the peak values in single apples can reach up to 2.16 mg/kg (6). Thus, there is evidence that considerable
amounts of residues of antimycotic agents could persist in at least
certain food items for quite a long time.
 |
COMMON ANTIFUNGAL MECHANISM OF ALL AZOLES AGAINST ALL FUNGI, BOTH
PLANT AND HUMAN PATHOGENS |
Within the group of azoles various chemical derivatives are
available, differing either in their characteristic imidazole or
triazole ring or in the side chain. At the moment, some of these
derivatives are either used medically or are under clinical evaluation
(22). Other derivatives are used in agriculture but not in
medicine. All azoles, irrespective of their distinctive chemical
structure and variable biological properties, interact and target to
the same active site in a fungal enzyme (7). Their
mechanism is based on interference with the activity of fungal
lanosterol 14
-demethylase, a member of the cytochrome P450
family. Fungal lanosterol 14
-demethylase is responsible for
transforming lanosterol to ergosterol, which is an essential constituent of fungal cytoplasmic membrane. The inhibition of ergosterol formation would result in fungal cell wall disorganization and, finally, stop fungal growth. The mode of action of azoles, therefore, is fungistatic rather than fungicidal. (The term
"fungicides," which is used in agriculture for this type of
pesticide, is misleading). The strength and efficiency of antifungal
activities vary strongly among the different azole derivatives. This is
illustrated by the different MICs, ranging from about 0.075 to 8 mg/liter for azole-susceptible fungal strains. This implies that on
plant surfaces and certain food items, the concentration of azole
residues could exceed or reach the MICs for most normal plant as well
as human pathogenic fungi and persist for several months.
 |
MECHANISMS OF RESISTANCE TO ALL AZOLES |
Most but not all fungi are primarily susceptible to azoles. Some
fungi are intrinsically resistant because ergosterol is not required
for their cell wall and membrane formation, e.g.,
Pneumocystis spp. At least three different resistance
mechanisms towards the azole group of antimycotics have been identified
(24) and are summarized as follows: (i) exclusion or even
active efflux from the fungi. Azole resistance is related to increased
export from the fungal cell. Efflux pumps from the CDR family (members
of the ATP binding cassette transporters) as well as MDR1 (a major facilitator) may be active. Several different CDR1 genes have been
found in a fungal cell whereby some are involved in azole resistance.
(ii) Resistance mechanisms may be based on structural alterations in
the target fungal enzyme. (iii) Resistance may stem from overproduction
of the target fungal enzyme.
Multidrug resistance, which means several resistance mechanisms
occurring in one resistant strain, is also frequently observed. Genetic
alterations may render an intrinsically susceptible strain resistant
and, finally, result in the development of a permanent phenotype.
Haploid fungal cells, such as Candida glabrata, might be
more prone to such events (23). In contrast to bacteria, resistance carried on a plasmid, which would be able to spread easily
from one cell to another, has not yet been described in fungi, so that
in general the development of resistance in a population is more
gradual. On the other hand, transient gene expression may temporarily
render a strain phenotypically resistant. It has been observed that the
production of CDR1 mRNA varies with different growth phases and
physiological conditions, which in turn results in a phenomenon of
growth cycle-dependent susceptibility of fungi (9).
 |
INCREASING INCIDENCE OF RESISTANCE TO AZOLES AMONG FUNGAL HUMAN
PATHOGENS |
Azole resistance appears to be emerging as a serious problem in
patients treated for yeast infections (24); in particular, the development of azole resistance in C. glabrata is
becoming a major concern (4, 19). There are three ways by
which patients may acquire azole-resistant fungi: (i) at the beginning,
the infecting or colonizing strain is susceptible but mutates and
develops azole resistance; (ii) the patient harbors a heterogeneous
population and the inherently resistant variant is selected during
treatment and exposure to antimycotics; or (iii) the patient acquires
an inherently resistant strain from the external milieu.
Azole-resistant Candida are found in patients not previously
exposed to antifungal agents (24).
There is no doubt any more that resistance in fungal strains can
develop in patients during prolonged treatment with azoles (13). On the other hand, resistant strains could also
develop in the surrounding environment and gain access to humans
afterwards. It was reported that a certain extent of airborne
cryptococci taken up by AIDS patients and other immunocompromised
patients were resistant prior to drug treatment (17).
Issatchenkia orientalis (Candida krusei) and
certain molds are even intrinsically resistant to some azoles because
of a low uptake of these agents into the fungal cell (19).
 |
ADDITIONAL PROBLEMS WITH FUNGI RESISTANT TO AZOLES |
Yeasts which are highly resistant to azoles pose an increasing
threat to patients (24). It has to be kept in mind that
the acquisition of certain resistance mechanisms, such as efflux pumps, would at the same time lower the susceptibility of such strains to
other nonrelated antimycotics. Some of these pumps, the major facilitators for example, can confer resistance to azoles as well as to
a broad spectrum of other antifungals such as cycloheximide, benztriazoles, and other agents (24). In such a case the
remaining options for an effective therapy are modest.
Other cellular functions also may be altered concomitantly with
resistance properties. The increase in azole resistance might eventually lead to an increase in virulence. In a particular laboratory mutant of Candida albicans, the azole-resistant variant
produced much higher amounts of extracellular aspartic proteinases,
which represent important virulence factors; hence, this resistant
mutant was much more virulent in mice than the azole-susceptible parent strain (3). Additionally, it has been reported that some
yeasts are able to form hyphae even in the presence of azoles and are therefore more pathogenic than others (24). Moreover,
phenotypic switching, which has been supposed to be involved in
virulence, could also be hampered in azole-resistant fungi
(20). Consequently, infection of humans by such resistant
pathogens would be even more difficult to control by host defense mechanisms.
 |
DOES THE USE OF AZOLES IN AGRICULTURE EXERT A SELECTIVE PRESSURE ON
HUMAN PATHOGENIC FUNGI? |
It is generally accepted that a strong and persistent
antimicrobial pressure on a complex microbial population will lead to selection of resistant strains, particularly if the antimicrobial agents exert only a microbial static but not a microbicidal effect. This has been found to occur in fungi, too; for example,
benzimidazoles, a group of antifungals which differ both chemically and
biologically from azoles, heralded a revolution in the control of
fungal plant diseases when they were initially introduced. However,
benzimidazole-resistant strains, which were able to survive as fit as
the naturally existing fungi in nature, emerged soon afterwards
(15).
The development of resistance in plant pathogenic fungi to azoles is
more complex and is generated slowly in small steps. Although it has
been considered that the risk of selecting azoles-resistant strains is
low, there have been reports claiming that some plant pathogenic fungi
have indeed acquired azole resistance (15).
It is anticipated that the excessive use of azoles in agriculture would
not only influence the plant pathogenic species but also would
inevitably attack susceptible species of the saprophytic flora. These
innocent bystanders, however, actively regulate the growth of
pathogenic fungi and consequently play a beneficial role
(8). Furthermore, such a disequilibration in the ecology of the fungal flora might also affect the population of medically important fungi. One possible consequence is that certain naturally existing human pathogenic fungi might survive and multiply. In particular those strains which have acquired azole resistance will
profit from the selective pressure. This would greatly increase the
risks and chances for humans to encounter such resistant microbes.
Many potentially human pathogenic fungi such as
Coccidioides, Histoplasma,
Aspergillus, and Cryptococcus have their natural habitat in the environment, including plants and food items
(16). These facts are also true for most yeasts (Table
1). As a matter of fact, only a few
species of yeasts exist as normal flora of humans. This means that in
many instances the infecting fungal organisms are taken up from the
surrounding environment.
Although there is at the moment no concrete proof of whether the
azole-resistance phenotype of human pathogenic fungi is induced by the
extensive use of these agents for plant protection, it is obvious that
the population of resistant strains in the environment could be
enriched by the exertion of such a prolonged selective pressure. Hence,
the chance arises that an individual will be exposed to resistant fungi.
 |
CAN THE DIETARY INTAKE OF AZOLES EXERT A SELECTIVE PRESSURE ON
FUNGI COLONIZING HUMANS? |
A second medical concern, possibly of minor importance, would be
the influence of azoles towards the fungal flora of human consumers. It
has been reported that the dietary intake of azole residues generally
does not reach a toxic level (6) or cause any harmful
effects to consumers. Otherwise, the use of such pesticides would be
strictly prohibited by the Food Quality Protection Act (21). However, it can be argued that these antimicrobial
agents might exert a selective pressure on the colonizing
Candida spp., in at least certain scenarios.
 |
CONCLUSIONS |
As a matter of fact, there is still no clear evidence for a
correlation between the agricultural use of azoles and the increase in
antimycotic resistance in human pathogenic fungi. A lot more scientific
studies should be carried out to further understand this issue. Further
work should elaborate on, for example, epidemiological studies of
resistant fungi in humans and nature, the effect of selection of
resistant fungi by long-term application of inhibitory or subinhibitory
concentrations of azoles, and the increase in fungal virulence induced
by such mechanisms. Nevertheless, as long as there is no convincing
proof indicating that the massive agricultural use of azoles is
absolutely independent from the increasing incidences of resistant
human pathogenic fungi, extra care should be taken in terms of the
application of azoles in agriculture. A more judicious antimycotic
usage in agriculture should be observed. Indeed, many alternative
antimycotics are available and, in principle, these alternative agents
could replace the presently used fungistatic azoles in agriculture.
Some reports have pointed out that the need for azoles is not
always compelling. For instance, treating
Fusarium-contaminated cereal grains indeed did not reduce
the mycotoxin load (10). Treating turf grass with azoles
(14) is also not indispensable.
In the final risk assessment for the use of azoles, not only the
toxicological aspects but also the possibility of induction and/or
selection of resistant human pathogenic fungi should be taken into
account. In the past few years, there have been strong discussions on
the use of antibiotics for plant protection (11) and as
growth enhancers in animal feed (25). At least in the latter case, there is a consensus that antibiotics which are of medical
importance should no longer be used in animal feed (2).
The use of azoles clinically is of high priority, since there are only
a few available alternatives in medicine for prophylactic and
therapeutic treatment of yeast and other fungal infections. On the
other hand, it is obvious that the need for antimycotics in medicine is
increasing due to the rising incidences of fungal infections. Yeasts,
for example, are the fourth most common cause of nosocomial
infections (12).
 |
FOOTNOTES |
*
Mailing address: Institute for Medical Microbiology and
Hygiene, Faculty for Clinical Medicine Mannheim, University of
Heidelberg, Theodor Kutzer Ufer 1-3, D-68167 Mannheim, Germany. Phone:
49 621 383 2224. Fax: 49 621 383 3816. E-mail:
herbert.hof{at}imh.ma.uni-heidelberg.de.
The views expressed in this Commentary do not
necessarily reflect the views of the journal or of
ASM.
 |
REFERENCES |
| 1.
|
Cairns, T.,
E. G. Siegmund,
K. S. Chiu, and R. Nelson.
1989.
Residue characterization of triadimefon in grapes by gas chromatography and mass spectrometry/mass spectrometry.
Biomed. Environ. Mass Spectrom.
2:110-115.
|
| 2.
| European Union. 1998. Richtlinie 70/524 EWG
über Zusatzstoffe in der Tierernährung. Amtsblatt der
Europäischen Gemeinschaften. L: 351/4.
|
| 3.
|
Fekete-Forgacs, K.,
L. Gyüre, and B. Lenkey.
2000.
Changes of virulence factors accompanying the phenomenon of induced fluconazole resistance in Candida albicans.
Mycoses
43:273-279[Medline].
|
| 4.
|
Fidel, P. L.,
J. A. Vazquez, and J. D. Sobel.
1999.
Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans.
Clin. Microbiol. Rev.
12:80-96[Abstract/Free Full Text].
|
| 5.
|
Garland, S. M.,
R. C. Menary, and N. W. Davies.
1999.
Dissipation of propiconazole and tebuconazole in peppermint crops (Mentha piperita (Labiatae)) and their residues in distilled oils.
J. Agric. Food Chem.
47:294-298[Medline].
|
| 6.
|
Hamey, P. Y., and C. A. Harris.
1999.
The variation of pesticide residues in fruits and vegetables and the associated assessment of risk.
Regul. Toxicol. Pharmacol.
30:S34-S41[Medline].
|
| 7.
|
Ji, H.,
W. Zhang,
Y. Zhou,
M. Zhang,
J. Zhu,
Y. Song, and J. Lu.
2000.
A three-dimensional model of lanosterol 14alpha-demethylase of Candida albicans and its interaction with azole antifungals.
J. Med. Chem.
43:2493-2505[CrossRef][Medline].
|
| 8.
|
Liggitt, J.,
P. Jenkinson, and D. W. Parry.
1997.
The role of saprophytic microflora in the development of Fusarium ear blight of winter wheat caused by Fusarium culmorum.
Crop Prot.
16:679-685[CrossRef].
|
| 9.
|
Lyons, C. N., and T. C. White.
2000.
Transcriptional analyses of antifungal drug resistance in Candida albicans.
Antimicrob. Agents Chemother.
44:2296-2303[Abstract/Free Full Text].
|
| 10.
|
Martin, R. A., and H. W. Johnston.
1982.
Effects and control of Fusarium disease of cereal grains in the Atlantic provinces.
Can. J. Plant Pathol.
4:210-216.
|
| 11.
|
McManus, P. S.
2000.
Antibiotic use and microbial resistance in plant agriculture.
ASM News
66:448-449.
|
| 12.
|
Rangel-Frausto, M.,
T. Wiblin,
H. M. Blumberg,
L. Saiman,
J. Patterson,
M. Rinaldi,
M. Pfaller,
J. E. Edwards,
W. Jarvis,
J. Dawson,
R. P. Wenzel, and the NEMIS Study Group.
1999.
National epidemiology of mycoses survey (NEMIS): variations in rates of bloodstream infections due to Candida species in seven surgical intensive care units and six neonatal intensive care units.
Clin. Infect. Dis.
29:253-258[Medline].
|
| 13.
|
Ruhnke, M.,
A. Schmidt-Westhausen, and M. Trautmann.
1997.
In vitro activities of voriconazole (UK-109,496) against fluconazole-susceptible and resistant Candida albicans isolates from oral cavities of patients with human immunodeficiency virus infection.
Antimicrob. Agents Chemother.
41:575-577[Abstract].
|
| 14.
|
Runes, H. B.,
J. J. Jenkins, and J. A. Field.
1999.
Method for the analysis of triadimefon and ethofumesate from dislodgeable foliar residues on turfgrass by solid-phase extraction and in-vial elution.
J. Agric. Food Chem.
47:3252-3256[Medline].
|
| 15.
|
Russell, P. E.
1995.
Fungicide resistance: occurrence and mangement.
J. Agric. Sci.
124:317-323
|
| 16.
|
Schauer, F., and R. Hanschke.
1999.
Zur Taxonomie und Ökologie der Gattung Candida.
Mycoses
42(Suppl. 1):12-21.
|
| 17.
|
Schmalreck, A. F., and H. Hotzel.
2000.
Fourier-Transform-Infrarot-Spektroskopie, Molekularbiologische Methoden und Antimykotika-Empfindlichkeitsmuster zur Identifizierung und Differenzierung von Cryptococcus-Spezies.
Mycoses
43(Suppl. 1):61-68.
|
| 18.
|
Tomlin, C. D. S. (ed.).
1997.
The pesticide manual, 11th ed.
British Crop Protection Council, Surrey, United Kingdom.
|
| 19.
|
Vanden Bossche, H.,
P. Marichal, and F. C. Odds.
1994.
Molecular mechanisms of drug resistance in fungi.
Trends Microbiol.
2:393-400[CrossRef][Medline].
|
| 20.
|
Vargas, K.,
S. A. Messer,
M. Pfaller,
S. R. Lockhart,
J. T. Stapleton,
J. Hellstein, and D. R. Soll.
2000.
Elevated phenotypic switching and drug resistance of Candida albicans from human immunodeficiency virus-positive individuals prior to first thrush episode.
J. Clin. Microbiol.
38:3595-3607[Abstract/Free Full Text].
|
| 21.
|
Wagner, J. M.
1997.
Food Quality Protection Act: its impact on the pesticide industry.
Qual. Assur.
5:279-283[Medline].
|
| 22.
|
Walsh, T. J.,
M.-A. Viviani,
E. Arathoon,
C. Chou,
M. Ghannoum,
A. H. Groll, and F. C. Odds.
2000.
New targets and delivery systems for antifungal therapy.
Med. Mycol.
38(Suppl. 1):335-347.
|
| 23.
|
Warnock, D. W.,
J. Burke,
N. J. Cope,
E. M. Johnson,
N. A. von Fraunhofer, and E. W. Williams.
1988.
Fluconazole resistance in Candida glabrata.
Lancet
ii:1310.
|
| 24.
|
White, T. C.,
K. A. Marr, and R. A. Bowden.
1998.
Clinical, cellular, and molecular factors that contribute to antifungal drug resistance.
Clin. Microbiol. Rev.
11:382-402[Abstract/Free Full Text].
|
| 25.
|
Witte, W.
1998.
Medical consequences of antibiotic use in agriculture.
Science
279:996-997[Free Full Text].
|
| 26.
|
Yamazaki, Y., and T. Ninomiya.
1998.
Determination of bitertanol residues in strawberries by liquid chromatography with fluorescence detection and confirmation by gas chromatography/mass spectrometry.
J. AOAC
81:1252-1256.
|
Antimicrobial Agents and Chemotherapy, November 2001, p. 2987-2990, Vol. 45, No. 11
0066-4804/01/$04.00+0 DOI: 10.1128/AAC.45.11.2987-2990.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Beernaert, L. A., Pasmans, F., Van Waeyenberghe, L., Dorrestein, G. M., Verstappen, F., Vercammen, F., Haesebrouck, F., Martel, A.
(2009). Avian Aspergillus fumigatus Strains Resistant to both Itraconazole and Voriconazole. Antimicrob. Agents Chemother.
53: 2199-2201
[Abstract]
[Full Text]
-
Serfling, A., Wohlrab, J., Deising, H. B.
(2007). Treatment of a Clinically Relevant Plant-Pathogenic Fungus with an Agricultural Azole Causes Cross-Resistance to Medical Azoles and Potentiates Caspofungin Efficacy. Antimicrob. Agents Chemother.
51: 3672-3676
[Abstract]
[Full Text]
-
Garcia-Effron, G., Mellado, E., Gomez-Lopez, A., Alcazar-Fuoli, L., Cuenca-Estrella, M., Rodriguez-Tudela, J. L.
(2005). Differences in Interactions between Azole Drugs Related to Modifications in the 14-{alpha} Sterol Demethylase Gene (cyp51A) of Aspergillus fumigatus. Antimicrob. Agents Chemother.
49: 2119-2121
[Abstract]
[Full Text]